RR, Rodman and Renshaw, is the laughing stock of the biotech sector as far as research goes. You show your ignorance thinking they made a good call, you'll see Monday how bad they really are, just ask MAXM investors.
Specifics, RR intiates coverage of Maxim Pharmaceuticals on May 5, 2004 at outperform, stock closes at 8.05, MAXM has Melanoma drug up for FDA review. On Sept 16, 2004 RR downgrades to market perform, stock closes at 5.79. On Sept 20, RR downgrades to underperform, stock closes at 3.04. Is that specific enough , or you want more.
RR are the laughing stock of Wall Street analysts. No question about that. Don't you ever wonder why only they follow SUPG and no other brokerage houses outside of internet bulletins? Simply put they are the kings of death spiral financings, and are tied to SUPG at the hip so of course they are going to give a glowing review. The question is why aren't Merrill, Schwab, etc doing the same? Answer is because SUPG is a lame company.